Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Duality Biotherapeutics, Inc. ( (HK:9606) ).
Duality Biotherapeutics, Inc. has announced the scheduling of an extraordinary general meeting (EGM) to be held on December 30, 2025, in Shanghai, China. The meeting will determine the identity of shareholders eligible to attend and vote, with a book closure period set from December 23 to December 30, 2025. This announcement is significant as it outlines the company’s procedural steps in engaging with its shareholders, potentially impacting shareholder relations and corporate governance practices.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. operates in the biotherapeutics industry, focusing on developing innovative therapeutic solutions. The company is incorporated in the Cayman Islands and is listed on the Stock Exchange of Hong Kong.
Average Trading Volume: 1,437,997
Technical Sentiment Signal: Hold
Current Market Cap: HK$29.86B
For detailed information about 9606 stock, go to TipRanks’ Stock Analysis page.